AtriCure, Inc. 10-Q Summary: Period Ended June 30, 2005
Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 2005. AtriCure, Inc. is a medical device company focused on the surgical treatment of atrial fibrillation (AF) using its Bipolar Ablation System. The company sells primarily to hospitals and clinics in the U.S. and internationally. As of the reporting date, the company was pre-IPO, having filed for an initial public offering (IPO) which was consummated on August 10, 2005, shortly after the period end.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2005 | Six Months Ended June 30, 2004 |
|---|---|---|
| Revenues | $15,228,179 | $8,926,876 |
| Gross Profit | $11,330,538 | $6,451,533 |
| Gross Margin | 74.4% | 72.3% |
| Net Loss (Available to Common) | $(4,709,016) | $(3,304,062) |
| Loss Per Share (Basic/Diluted) | $(2.50) | $(1.83) |
| Cash and Cash Equivalents (End of Period) | $1,090,680 | $8,305,641 |
| Working Capital | $2,274,393 | $6,590,173 |
| Accumulated Deficit | $(34,360,062) | $(29,633,009) |
Debt and Liquidity: As of June 30, 2005, there were no amounts outstanding under a $5.0 million credit facility with Lighthouse Capital Partners. However, the company drew down $1.5 million under this facility in July 2005. The company held $1.1 million in cash at period end, with a significant portion of assets tied up in deferred offering costs ($2.1 million) and an advance payment for the acquisition of Enable Medical Corporation ($0.5 million).
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 71% year-over-year for the six-month period, driven by a 77% increase in unit sales volume and the introduction of new products. International sales grew to approximately 9.7% of total revenue.
- Expense Increases: Operating expenses rose significantly. Research and Development (R&D) expenses increased 112% to $3.7 million due to hiring and expanded clinical trials. Selling, General, and Administrative (SG&A) expenses increased 70% to $10.4 million, primarily due to headcount expansion in sales and marketing.
- Cash Burn: Net cash used in operating activities increased to $2.7 million from $1.3 million in the prior year period. Cash and cash equivalents declined by approximately $4.1 million during the six months.
- Preferred Stock Interest: The company recorded $1.95 million in preferred stock interest expense for the six months, reflecting the accrual of a 15% annual return on Series A and B preferred stock.
Guidance, Outlook, Risks, and Subsequent Events
Subsequent Events (Post-June 30, 2005):
- Initial Public Offering: On August 10, 2005, the company completed an IPO of 4.6 million shares at $12.00 per share, raising approximately $46.3 million in gross proceeds (before expenses). All outstanding preferred stock converted to common stock upon closing.
- Acquisition of Enable Medical Corporation: On August 10, 2005, the company acquired Enable Medical Corporation for $7.0 million to gain control over the manufacturing of Isolator handpieces.
- New Development Agreement: In July 2005, the company entered into an agreement with UST Inc. to develop a High Intensity Focused Ultrasound (HIFU) system, involving upfront fees and future royalties.
Outlook and Risks:
- Regulatory Risk (Critical): In June 2005, the FDA denied 510(k) clearance for the company's system to ablate cardiac tissue, reclassifying it as a Class III device. The company must now pursue a Pre-Market Approval (PMA), a lengthier and more expensive process, to legally market the device for its primary use (treating AF). Currently, sales are based on off-label use.
- Market Acceptance: Future growth depends on the development of the "sole-therapy minimally invasive" market for AF treatment, which is not yet established.
- Supply Chain: The company relies on single-source suppliers for critical components, including the Ablation Sensing Unit (ASU).
- Profitability: Management expects operating expenses to continue to increase in absolute terms and as a percentage of revenue as the company expands sales, R&D, and regulatory efforts.
Investor Verification Checklist
- FDA Status: Verify the current status of the Pre-Market Approval (PMA) application for cardiac tissue ablation and the timeline for the RESTORE-SR clinical trial.
- Off-Label Promotion: Review the company's compliance with FDA regulations regarding the promotion of off-label uses and any history of regulatory warnings or investigations.
- Acquisition Integration: Assess the financial impact and integration progress of the Enable Medical Corporation acquisition.
- Capital Runway: Confirm the utilization of IPO proceeds and the company's ability to fund the expensive PMA process and clinical trials without further dilution.
- Supplier Concentration: Evaluate the risks associated with reliance on single-source suppliers for critical manufacturing components.